Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes.

Aoki A, Murata M, Asano T, Ikoma A, Sasaki M, Saito T, Otani T, Jinbo S, Ikeda N, Kawakami M, Ishikawa SE.

Cardiovasc Diabetol. 2013 Jan 9;12:11. doi: 10.1186/1475-2840-12-11.

2.

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.

Maser RE, Lenhard MJ, Sneider MB, Pohlig RT.

Endocr Pract. 2015 Jan;21(1):14-22. doi: 10.4158/EP14229.OR.

PMID:
25100392
3.

Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis.

Ramirez-Sandoval JC, Casanova I, Villar A, Gomez FE, Cruz C, Correa-Rotter R.

Perit Dial Int. 2016 May-Jun;36(3):262-8. doi: 10.3747/pdi.2014.00250. Epub 2015 Aug 20.

PMID:
26293840
4.

The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients.

Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ.

Cardiovasc Diabetol. 2014 Feb 24;13:52. doi: 10.1186/1475-2840-13-52.

5.

Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy.

Bourron O, Aubert CE, Liabeuf S, Cluzel P, Lajat-Kiss F, Dadon M, Komajda M, Mentaverri R, Brazier M, Pierucci A, Morel F, Jacqueminet S, Massy ZA, Hartemann A.

J Clin Endocrinol Metab. 2014 Nov;99(11):4250-8. doi: 10.1210/jc.2014-1047. Epub 2014 Jul 11.

PMID:
25013993
6.

Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients.

Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A, Yildiz A.

Clin J Am Soc Nephrol. 2012 Jun;7(6):965-73. doi: 10.2215/CJN.11191111. Epub 2012 Apr 5.

7.

Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers.

Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, Corder R, Lahiri A.

J Am Coll Cardiol. 2007 Dec 4;50(23):2218-25. Epub 2007 Nov 19.

8.
9.

Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.

Tavintharan S, Pek LT, Liu JJ, Ng XW, Yeoh LY, Su Chi L, Chee Fang S.

Diab Vasc Dis Res. 2014 Sep;11(5):359-62. doi: 10.1177/1479164114539712. Epub 2014 Jul 7.

PMID:
25005034
10.

Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.

Ashley DT, O'Sullivan EP, Davenport C, Devlin N, Crowley RK, McCaffrey N, Moyna NM, Smith D, O'Gorman DJ.

Metabolism. 2011 Jul;60(7):994-1000. doi: 10.1016/j.metabol.2010.10.001. Epub 2010 Nov 18.

PMID:
21087777
11.

Biomarkers of vascular calcification and mortality in patients with ESRD.

Scialla JJ, Kao WH, Crainiceanu C, Sozio SM, Oberai PC, Shafi T, Coresh J, Powe NR, Plantinga LC, Jaar BG, Parekh RS.

Clin J Am Soc Nephrol. 2014 Apr;9(4):745-55. doi: 10.2215/CJN.05450513. Epub 2014 Jan 23.

12.

Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study.

Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, Hawa G, Chapurlat R, Szulc P.

J Clin Endocrinol Metab. 2012 Apr;97(4):E575-83. doi: 10.1210/jc.2011-2836. Epub 2012 Feb 8.

PMID:
22319041
13.

Diabetes confers in vitro calcific potential on serum which associates with in vivo vascular calcification.

Patidar A, Singh DK, Thakur S, Winocour P, Farrington K, Baydoun AR.

Clin Sci (Lond). 2017 May 1;131(10):991-1000. doi: 10.1042/CS20160882. Epub 2017 Mar 20.

PMID:
28320782
14.

Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein.

Liabeuf S, Bourron O, Vemeer C, Theuwissen E, Magdeleyns E, Aubert CE, Brazier M, Mentaverri R, Hartemann A, Massy ZA.

Cardiovasc Diabetol. 2014 Apr 24;13:85. doi: 10.1186/1475-2840-13-85. Erratum in: Cardiovasc Diabetol. 2015;14:9. Olivier, Bourron [corrected to Bourron, Olivier].

15.

Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes.

Esteghamati A, Aflatoonian M, Rad MV, Mazaheri T, Mousavizadeh M, Nakhjavani M, Noshad S.

Arch Cardiovasc Dis. 2015 Aug-Sep;108(8-9):412-9. doi: 10.1016/j.acvd.2015.01.015. Epub 2015 Jul 13.

16.

Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function.

Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K.

Diabetes Res Clin Pract. 2012 Jul;97(1):158-65. doi: 10.1016/j.diabres.2012.01.038. Epub 2012 Mar 3.

PMID:
22386825
17.

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.

Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM.

Diabetologia. 2008 Nov;51(11):2100-7. doi: 10.1007/s00125-008-1123-8. Epub 2008 Aug 22.

PMID:
18719882
18.

Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus.

Ogawa-Furuya N, Yamaguchi T, Yamamoto M, Kanazawa I, Sugimoto T.

Osteoporos Int. 2013 Aug;24(8):2223-30. doi: 10.1007/s00198-013-2289-6. Epub 2013 Apr 6.

PMID:
23563931
19.

Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients.

Ishiyama M, Suzuki E, Katsuda J, Murase H, Tajima Y, Horikawa Y, Goto S, Fujita T, Takeda J.

Diabetes Res Clin Pract. 2009 Aug;85(2):189-96. doi: 10.1016/j.diabres.2009.04.023. Epub 2009 Jun 3.

PMID:
19497632
20.

Vascular calcification biomarkers and peripheral arterial disease.

Kapetanios D, Karkos C, Giagtzidis I, Papazoglou K, Kiroplastis K, Spyridis C.

Int Angiol. 2016 Oct;35(5):455-9. Epub 2015 Jun 5. Review.

PMID:
26044839

Supplemental Content

Support Center